192 related articles for article (PubMed ID: 35202353)
41. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
[TBL] [Abstract][Full Text] [Related]
42. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.
Am Rev Respir Dis; 1984 Jun; 129(6):921-8. PubMed ID: 6375490
[TBL] [Abstract][Full Text] [Related]
43. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
[TBL] [Abstract][Full Text] [Related]
44. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
45. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
46. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
Tam CM; Chan SL; Lam CW; Leung CC; Kam KM; Morris JS; Mitchison DA
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1726-33. PubMed ID: 9620898
[TBL] [Abstract][Full Text] [Related]
47. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
[TBL] [Abstract][Full Text] [Related]
48. Six-month therapy for abdominal tuberculosis.
Jullien S; Jain S; Ryan H; Ahuja V
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).
el-Sadr WM; Perlman DC; Matts JP; Nelson ET; Cohn DL; Salomon N; Olibrice M; Medard F; Chirgwin KD; Mildvan D; Jones BE; Telzak EE; Klein O; Heifets L; Hafner R
Clin Infect Dis; 1998 May; 26(5):1148-58. PubMed ID: 9597244
[TBL] [Abstract][Full Text] [Related]
50. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Velayutham B; Jawahar MS; Nair D; Navaneethapandian P; Ponnuraja C; Chandrasekaran K; Narayan Sivaramakrishnan G; Makesh Kumar M; Paul Kumaran P; Ramesh Kumar S; Baskaran D; Bella Devaleenal D; Sirasanambati DR; Vasantha M; Palaniyandi P; Ramachandran G; Uma Devi KR; Elizabeth Hannah L; Sekar G; Radhakrishnan A; Kalaiselvi D; Dhanalakshmi A; Thiruvalluvan E; Raja Sakthivel M; Mahilmaran A; Sridhar R; Jayabal L; Rathinam P; Angamuthu P; Soorappa Ponnusamy K; Venkatesan P; Natrajan M; Prasad Tripathy S; Swaminathan S
Trop Med Int Health; 2020 Apr; 25(4):483-495. PubMed ID: 31944502
[TBL] [Abstract][Full Text] [Related]
51. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
52. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
[TBL] [Abstract][Full Text] [Related]
53. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
54. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
55. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
[TBL] [Abstract][Full Text] [Related]
56. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
[TBL] [Abstract][Full Text] [Related]
57. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
58. Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case.
Rodrigues Carvalho S; Silva I; Leiria-Pinto P; Rosado-Pinto J
Allergol Immunopathol (Madr); 2009; 37(6):336-8. PubMed ID: 19875222
[No Abstract] [Full Text] [Related]
59. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
Dawson R; Narunsky K; Carman D; Gupte N; Whitelaw A; Efron A; Barnes GL; Hoffman J; Chaisson RE; McIlleron H; Dorman SE
Int J Tuberc Lung Dis; 2015 Jul; 19(7):780-6. PubMed ID: 26056101
[TBL] [Abstract][Full Text] [Related]
60. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
